Neuro-Bio
Abingdon
About Neuro-Bio
Neuro-Bio is a start-up company focused on the development of novel, effective therapeutics for neurodegenerative disorders such as Alzheimer’s, Parkinson’s and Motor Neuron Disease. The Company’s uniqueness lies in its innovative identification of the initial trigger of neurodegeneration - this has been developed throughout Baroness Professor Susan Greenfield’s highly credited 40 year career in neuroscience.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $14.7M
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2017)
- Website: neuro-bio.com
- Phone: +44 (0) 1235 420085
Industries & Categories
Biotechnology, Health Care, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/neuro-bio-143553 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.